A new study from South Africa shows that the Pfizer / Bioendech vaccine is only 33% effective against the Omigron variant of the corona virus, but those with the Omigran variant are less likely to go to the hospital than those with the original mutation. Virus.
The data comes from Discovery Health, a major health insurance company covering 3.7 million people in South Africa. The team there, along with researchers from the South African Medical Research Council, looked at claims data from Omigron’s dominance across South Africa and compared it with previous data.
They examined 211,000 positive corona virus test results, of which 41% were taken from adult members who had been given two doses of the Pfizer vaccine. The company estimates that Omicron was involved in 78,000 cases between November 15 and the first week of December.
They estimate that the risk of end-of-hospital exposure from Govit-19 to omigran infections in adults is 29% lower than in the original virus, but that children are 20% more likely to be hospitalized. This year was compared to the first strains of the virus, not to the alpha or beta variants that were prevalent in South Africa.
They said two doses of the Pfizer vaccine were 33% safe against infection overall, but 70% effective in preventing serious complications, including hospitalization.
“National data show a rapid steep path of new infections compared to the fourth previous wave driven by Omigran. National data show a rapid increase in both new infections and test positive rates in the first three weeks of this wave, indicating a very pervasive variation with rapid social spread of the disease,” said Dr. Discovery. Ryan Noch said. .
“Overall, the risk of re-infection following a previous infection has increased over time, with Omigron causing significantly higher resumption rates compared to previous variants,” Discovery Health chief health analyst Auxury Shirley Cole said in a statement. Collie said those on the delta wave in South Africa have a 40% higher risk of re-infection with Omigran and those with beta dominance have a 60% higher risk of re-infection with Omigran.
“Although children are less likely to have severe complications following Govit-19, Discovery Health data indicate that children under the age of 18 are 20% more likely to develop complications of Govit-19 if they are infected with Omigran.” The goalie added.
“This requires initial data and careful follow-up. However, the National Institute for Infectious Diseases of South Africa (NICD) has recently seen an increase in child enrollment during the third wave of epidemics in South Africa (June to September 2021) and is now on the fourth wave., Under five. They see a similar increase in pediatric admissions.In event reports from hospitals in South Africa indicate that the majority of Kovit-19 diagnoses in hospitalized children are co-occurring – many children admitted for non-Govt-19 conditions and not experiencing Govt-19 complications have a positive test for Govt. -19 In regular screening tests. “